SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 8.25% Stake in Accelerate Diagnostics

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.25% in Accelerate Diagnostics, Inc., totaling 2,078,000 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Accelerate Diagnostics, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 2,078,000 shares of Accelerate Diagnostics, Inc. common stock.
• This ownership represents 8.25% of the issuer's common stock.
• The Reporting Persons hold shared voting power and shared dispositive power over all 2,078,000 shares.
• Armistice Capital, LLC is identified as an investment adviser, and Steven Boyd as a parent holding company and individual.
• The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, for which Armistice Capital, LLC acts as the investment manager.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or future prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm in a publicly traded company within the diagnostics industry. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment.

Related Party Transactions

• Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends and proceeds from the sale of the reported securities.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional stake may influence investor perception and potentially stock liquidity.

Key Dates

Keywords

Accelerate Diagnostics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional ownership